Click here for slides on this topic


Coronary revascularization

Any cardiology procedure, including coronary artery bypass graft (CABG), percutaneous coronary angiography (PTCA), or stenting, that is intended to increase blood flow to the coronary arteries.
The following content matched the glossary term: Coronary revascularization

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

JUPITER: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-reactive Protein

Top

Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. The Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, double-blind, placebo-controlled trial which sought to examine whether rosuvastatin treatment compared with placebo would decrease the rate of first cardiovascular (CV) events.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial

Top

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes an analysis of baseline data from the ORIGIN trialRamachandran A, Riddle MC, Kabali C, Gerstein HC for the ORIGIN Investigators. Diabetes Care. 2012 35 749 753. The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial is a global trial assessing whether targeting normal FPG levels with basal insulin glargine reduces cardiovascular outcomes compared with standard care among people taking 0 or 1 oral antidiabetes drugs (OADs).

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study

Top

Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; on behalf of the FIELD Study Investigators. Benefits and safety of long term fenofibrate therapy in people with type 2 diabetes and renal impairment the FIELD study. Diabetes Care. 2012 Feb;35(2):218-225. OBJECTIVE Diabetic patients with moderate renal impairment are at particular cardiovascular risk.

Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus

Top

Gimeno-Orna JA, Faure-Nogueras E, Castro-Alonso FJ, Boned-Juliani B. Ability of retinopathy to predict cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 2009;103(10):1364-1367. It is important identify patients with very high cardiovascular risk to intensify their therapy. Our aim was to assess the association between retinopathy and incident cardiovascular events (cardiovascular disease [CVD]) in patients with type 2 diabetes mellitus (DM).

A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease

Top

The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. N Engl J Med. 2009 Jun 7. [Epub ahead of print]. BACKGROUND: Optimal treatment for patients with both type 2 diabetes mellitus and stable ischemic heart disease has not been established.

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

Top

Young LH, Wackers FJ, Chyun DA, et al for the DIAD Investigators.Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547-1555. Coronary artery disease (CAD) is the major cause of mortality and morbidity in patients with type 2 diabetes. But the utility of screening patients with type 2 diabetes for asymptomatic CAD is controversial.

1 2 3 4 Next 

Slide Library Results

Search Results for: Coronary revascularization Slides Found: 51
Elective Coronary Revascularization in Patients With Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Design
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
ACCELERATE Evacetrapib Does Not Lower CV Events in High-Risk Patients | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility